Avid Radiopharmaceuticals is a technology company.
Avid Radiopharmaceuticals has raised $44.0M across 2 funding rounds.
Avid Radiopharmaceuticals has raised $44.0M in total across 2 funding rounds.
Avid Radiopharmaceuticals is a biotechnology company specializing in molecular imaging agents for early detection of neurodegenerative diseases, operating as a wholly owned subsidiary of Eli Lilly and Company.[1][2][3] It develops PET imaging diagnostics like Amyvid (approved 2012 for amyloid plaques in Alzheimer's) and Tauvid (approved 2020 for tau tangles), targeting conditions such as Alzheimer's disease, Parkinson's, Dementia with Lewy Bodies, and diabetes to enable pre-symptomatic intervention and accelerate new medicine development.[3][4][5] Serving clinicians, pharmaceutical researchers, and patients with unmet needs in neurology, Avid addresses the critical problem of late diagnosis by detecting pathological changes before symptoms emerge, with reported revenue of $55.4 million and a pipeline showing growth potential in precision medicine.[1][3]
Avid Radiopharmaceuticals was founded in July 2005 by Dr. Daniel Skovronsky, M.D., Ph.D., former Scientific Director at the University of Pennsylvania’s Center for Neurodegenerative Disease Research, with the goal of creating injectable dyes that cross the blood-brain barrier to bind amyloid plaques for PET imaging.[5][7] Building on pioneering work by William Klunk and Chester Mathis on Pittsburgh Compound B, Skovronsky secured $500,000 in seed funding from BioAdvance and started in a single lab at the University City Science Center incubator in Philadelphia.[5][7][8] Key early traction included FDA advisory approval recommendation in 2011 for florbetapir (Amyvid), marking the first FDA-approved method to directly visualize Alzheimer's pathology in living patients; the company expanded facilities fivefold to 24,500 sq ft for radiopharmaceutical production and was acquired by Eli Lilly, evolving from a startup to a diagnostics leader.[3][5][7]
Avid rides the wave of precision diagnostics in neurodegenerative diseases, where aging populations drive demand for early detection amid failures in late-stage Alzheimer's therapies.[3][5] Timing aligns with advances in PET imaging and AI-enhanced analysis, amplified by post-2020 approvals like Tauvid amid rising biotech investment in brain health.[3][4] Market forces favoring Avid include regulatory support (FDA approvals), pharma needs for biomarkers in trials, and global health priorities for dementia (affecting millions).[1][5] As a Lilly subsidiary, it influences the ecosystem by accelerating drug discovery—e.g., validating amyloid reduction in trials—and fostering innovation hubs like Philadelphia's Science Center, bridging academia, startups, and big pharma.[7][8]
Avid is poised to expand its pipeline with next-generation diagnostics unlocking emerging science in neurodegeneration, potentially integrating with therapeutics like anti-amyloid drugs.[3] Trends like multimodal imaging, AI for scan analysis, and combination diagnostic-therapeutic platforms will shape its path, enhancing Eli Lilly's neurology dominance.[1][3][4] Its influence may evolve toward broader chronic disease applications (e.g., diabetes, Parkinson's), solidifying early detection as a cornerstone of personalized medicine and transforming patient outcomes from reactive to proactive care.[1][3]
Avid Radiopharmaceuticals has raised $44.0M in total across 2 funding rounds.
Avid Radiopharmaceuticals's investors include MPM Capital, Tectonic Ventures.
Avid Radiopharmaceuticals has raised $44.0M across 2 funding rounds. Most recently, it raised $35.0M Series D in May 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2009 | $35.0M Series D | MPM Capital | |
| Jan 1, 2006 | $9.0M Series A | Tectonic Ventures |